Quince Therapeutics Q3 net loss $5.5M; Phase 3 NEAT enrollment at 32 patients

Quince Therapeutics, Inc.

2024-Q3 EPS reported -$1.03

Phase 3 NEAT trial enrolled 32 patients; on track to complete enrollment in Q2 2025 with topline results in Q4 2025.
Cash, equivalents, and short-term investments of $47.8M; runway expected into 2026 through topline results.
Net loss of $5.5M ($0.13 per share) for Q3 2024; R&D expenses $4.9M, G&A expenses $3.6M.
Plans to initiate a Phase 2 Duchenne muscular dystrophy study in 2025.
Identified 11 potential new rare disease indications for EryDex beyond A-T and DMD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.